Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · see citing works

Untangling the ErbB signalling network

Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · see citing works

Real time quantitative PCR.Preprint

Heid, C., Stevens, J., Livak, K. J., & Williams, P. (1996) · Genome Research · doi:10.1101/gr.6.10.986 · Cited by 6,180 · see citing works

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,355 · see citing works

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084 · see citing works

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

Geyer, C. E., Forster, J. K., Lindquist, D. L., Chan, S. Y. T., Romieu, C. G., Pieńkowski, T., Jagiełło-Gruszfeld, A., Crown, J. P., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,426 · see citing works

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Vogel, C. L., Cobleigh, M., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.719 · Cited by 3,240 · see citing works

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · see citing works

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of <i>HER2</i>-Overexpressing Metastatic Breast Cancer

Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860 · see citing works

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · see citing works

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

Cho, H., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., & Leahy, D. J. (2003) · Nature · doi:10.1038/nature01392 · Cited by 1,615 · see citing works

ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

Graus-Porta, D., Beerli, R. R., Daly, J. M., & Hynes, N. E. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,593 · see citing works

Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer

Joensuu, H., Kellokumpu‐Lehtinen, P., Bono, P., Alanko, T., Kataja, V. V., Asola, R., Utriainen, T., Kokko, R., Hemminki, A., Tarkkanen, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053028 · Cited by 1,401 · see citing works

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

Franklin, M. C., Carey, K. D., Vajdos, F. F., Leahy, D. J., de Vos, A. M., & Sliwkowski, M. X. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00083-2 · Cited by 1,123 · see citing works

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001 · see citing works

The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy

Ross, J. S., & Fletcher, J. A. (1998) · Stem Cells · doi:10.1002/stem.160413 · Cited by 990 · see citing works

Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells

Konecny, G. E., Pegram, M. D., Venkatesan, N., Finn, R. S., Yang, G., Rahmeh, M., Untch, M., Rusnak, D. W., Spehar, G. M., Mullin, R. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1182 · Cited by 916 · see citing works

Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)

Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 884 · see citing works

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00097-1 · Cited by 873 · see citing works

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D. G., Kaye, S. B., Gianni, L., Harris, A., Bjork, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.100 · Cited by 829 · see citing works

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

Nahta, R., Yuan, L. X. H., Zhang, B., Kobayashi, R., & Esteva, F. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3841 · Cited by 793 · see citing works

Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.

Pinkas‐Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L. N., Lavi, S., Seger, R., Ratzkin, B. J., Sela, M., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00603.x · Cited by 770 · see citing works

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.

Molina, M. A., Codony‐Servat, J., Albanell, J., Rojo, F., Arribas, J., & Baselga, J. M. (2001) · PubMed · Cited by 766 · see citing works

p185 HER2 Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor

Hudziak, R. M., Phillips, G. D. L., Winget, M., FENDLY, B. M., Shepard, H. M., & Ullrich, A. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.3.1165-1172.1989 · Cited by 750 · see citing works

Herceptin acts as an anti-angiogenic cocktail

Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K. (2002) · Nature · doi:10.1038/416279b · Cited by 623 · see citing works

Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.

Yakes, F. M., Chinratanalab, W., Ritter, C. A., King, W., SEELIG, S. A., & Arteaga, C. L. (2002) · PubMed · Cited by 611 · see citing works

The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells

Nahta, R., Hung, M., & Esteva, F. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3856 · Cited by 607 · see citing works

Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.

Moulder, S. L., Yakes, F. M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., & Arteaga, C. L. (2001) · PubMed · Cited by 548 · see citing works

Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin

Austin, C. D., Mazière, A. M. G. L. D., Pisacane, P. I., van Dijk, S., Eigenbrot, C. W., Sliwkowski, M. X., Klumperman, J., & Scheller, R. H. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-07-0591 · Cited by 498 · see citing works

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

Engelman, J. A., Janne, P. A., Mermel, C. H., Pearlberg, J., Mukohara, T., Fleet, C., Cichowski, K. M., Johnson, B. E., & Cantley, L. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409773102 · Cited by 494 · see citing works

Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer

Robert, N. J., Leyland-Jones, B. R., Asmar, L., Belt, R. J., Ilegbodu, D., Loesch, D. M., Raju, R. N., Valentine, E., Sayre, R., Cobleigh, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.1764 · Cited by 479 · see citing works

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

Wang, S. E., Narasanna, A., Pérez-Torres, M., Xiang, B., Wu, F. Y., Yang, S., Carpenter, G. F., Gazdar, A. F., Muthuswamy, S. K., & Arteaga, C. L. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.05.023 · Cited by 474 · see citing works

Phase II Study of Efficacy, Safety, and Pharmacokinetics of Trastuzumab Monotherapy Administered on a 3-Weekly Schedule

Baselga, J., Carbonell, X., Castañeda-Soto, N.-J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.014 · Cited by 427 · see citing works

Increased<i>HER2</i>Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor–Positive Non–Small-Cell Lung Cancer Patients

Cappuzzo, F., Varella-Garcia, M., Shigematsu, H., Domenichini, I., Bartolini, S., Ceresoli, G. L., Rossi, E., Ludovini, V., Gregorc, V., Toschi, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.111 · Cited by 369 · see citing works

Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.

Arteaga, C. L., Hurd, S. D., Winnier, A. R., Johnson, M. D., Fendly, B. M., & Forbes, J. T. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116871 · Cited by 359 · see citing works

ErbB-2 Amplification Inhibits Down-regulation and Induces Constitutive Activation of Both ErbB-2 and Epidermal Growth Factor Receptors

Worthylake, R. A., Opresko, L. K., & Wiley, H. S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.13.8865 · Cited by 326 · see citing works

ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27 Kip1 -Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency

Lane, H. A., Beuvink, I., Motoyama, A. B., Daly, J. M., Neve, R. M., & Hynes, N. E. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.9.3210-3223.2000 · Cited by 298 · see citing works

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.

Rusnak, D. W., Affleck, K., Cockerill, S. G., Stubberfield, C. R., Harris, R., Pagé, M., Smith, K. J., Guntrip, S. B., Carter, M. C., Shaw, R. J., et al. (2001) · PubMed · Cited by 294 · see citing works

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

Xia, W., Gerard, C. M., Liu, L.-H., Baudson, N., Ory, T., & Spector, N. L. (2005) · Oncogene · doi:10.1038/sj.onc.1208774 · Cited by 258 · see citing works

NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer.

Christianson, T. A., Doherty, J. K., Lin, Y.-J., et al. (1998) · PubMed · Cited by 253 · see citing works

The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.

Motoyama, A. B., Hynes, N. E., & Lane, H. A. (2002) · PubMed · Cited by 249 · see citing works

Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas

Hirsch, F. R., Varella-Garcia, M., Franklin, W. A., Veve, R., Chen, L., Helfrich, B., Zeng, C., Barón, A. E., & Bunn, P. A. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600286 · Cited by 246 · see citing works

Neoadjuvant Trastuzumab Induces Apoptosis in Primary Breast Cancers

Mohsin, S. K., Weiss, H. L., Gutierrez, M. C., Chamness, G. C., Schiff, R., DiGiovanna, M. P., Wang, C.-X., Hilsenbeck, S. G., Osborne, C. K., Allred, D. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.661 · Cited by 244 · see citing works

Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation

Anido, J., Scaltriti, M., Bech Serra, J. J., Josefat, B. S., Rojo Todo, F., Baselga, J., & Arribas, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601191 · Cited by 231 · see citing works

Relationship of Epidermal Growth Factor Receptor Expression to ErbB-2 Signaling Activity and Prognosis in Breast Cancer Patients

DiGiovanna, M. P., Stern, D. F., Edgerton, S. M., Whalen, S. G., Moore, D. H., & Thor, A. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.055 · Cited by 230 · see citing works

Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.

Diermeier, S., Horvath, G. L., Knuechel-Clarke, R., Hofstaedter, F., Szöllősi, J., & Brockhoff, G. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.12.008 · Cited by 192 · see citing works

Epidermal growth factor (EGF) stimulates EGF receptor synthesis.

Earp, H. S., Austin, K. S., Blaisdell, J. A., et al. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)89171-8 · Cited by 188 · see citing works

Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies.

Kasprzyk, P. G., Song, S. U., Fiore, P. P. D., & King, C. R. (1992) · PubMed · Cited by 151 · see citing works

Synergistic Interaction of the Neu Proto-Oncogene Product and Transforming Growth Factor α in the Mammary Epithelium of Transgenic Mice

Muller, W. J., Arteaga, C. L., Muthuswamy, S. K., Siegel, P. M., Webster, M. A., Cardiff, R. D., Meise, K. S., Li, F., Halter, S. A., & Coffey, R. J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5726 · Cited by 147 · see citing works

Herceptin‐induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down‐regulation of ErbB2

Longva, K. E., Pedersen, N. M., Haslekås, C., Stang, E., & Madshus, I. H. (2005) · International Journal of Cancer · doi:10.1002/ijc.21015 · Cited by 142 · see citing works

TGFα expression impairs Trastuzumab-induced HER2 downregulation

Valabrega, G., Montemurro, F., Sarotto, I., Petrelli, A., Rubini, P., Tacchetti, C., Aglietta, M., Comoglio, P. M., & Giordano, S. (2005) · Oncogene · doi:10.1038/sj.onc.1208478 · Cited by 129 · see citing works

Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-α bigenic mice

Lenferink, A. E. G., Simpson, J. F., Shawver, L. K., Coffey, R. J., Forbes, J. T., & Arteaga, C. L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.160564197 · Cited by 124 · see citing works

Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists.

Harwerth, I. M., Wels, W. S., Marte, B. M., & Hynes, N. E. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42160-6 · Cited by 123 · see citing works

HER2/Neu (ErbB2) Signaling to Rac1-Pak1 Is Temporally and Spatially Modulated by Transforming Growth Factor β

Wang, S. E., Shin, I., Wu, F. Y., Friedman, D. B., & Arteaga, C. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2071 · Cited by 107 · see citing works

ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4

Wang, L.-M., Kuo, A. H., Alimandi, M., Veri, M. C., Lee, C.-C., Kapoor, V., Ellmore, N., Chen, X.-H., & Pierce, J. H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6809 · Cited by 97 · see citing works

p185HER2 signal transduction in breast cancer cells

Scott, G. K., Dodson, J., Montgomery, P. A., et al. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98683-7 · Cited by 88 · see citing works

EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): Clinical activity and biologic predictors of response

Nl, S., Blackwell, K., Hurley, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.502 · Cited by 79 · see citing works

Epidermal growth factor (EGF) and hormones stimulate phosphoinositide hydrolysis and increase EGF receptor protein synthesis and mRNA levels in rat liver epithelial cells. Evidence for protein kinase C-dependent and -independent pathways.

Earp, H. S., Hepler, J. R., Petch, L., et al. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68324-3 · Cited by 77 · see citing works

HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: Preliminary phase 1 results in patients with solid tumors

Wong, K., Fracasso, P. M., Bukowski, R. M., Munster, P. N., Lynch, T. J., Abbas, R., Quinn, S. E., Zacharchuk, C., & Burris, H. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3018 · Cited by 57 · see citing works

Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells.

Shawver, L. K., Mann, E., Elliger, S. S., et al. (1994) · PubMed · Cited by 30 · see citing works

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048 · see citing works

Three-dimensional culture systems in cancer research: Focus on tumor spheroid model

Nath, S., & Devi, G. R. (2016) · Pharmacology &amp; Therapeutics · doi:10.1016/j.pharmthera.2016.03.013 · Cited by 919 · see citing works

Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker

Solca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C., Kraemer, O., Himmelsbach, F., Haaksma, E., & Adolf, G. R. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.197756 · Cited by 865 · see citing works

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663 · see citing works

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

Wheeler, D. L., Huang, S., Kruser, T. J., Nechrebecki, M. M., Armstrong, E. A., Benavente, S., Gondi, V, Hsu, K.-T., & Harari, P. M. (2008) · Oncogene · doi:10.1038/onc.2008.19 · Cited by 550 · see citing works

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

Zhang, S., Huang, W.-C., Li, P., Guo, H., Poh, S.-B., Brady, S. W., Xiong, Y., Tseng, L.-M., Li, S.-H., Ding, Z., et al. (2011) · Nature Medicine · doi:10.1038/nm.2309 · Cited by 515 · see citing works

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells

Shattuck, D. L., Miller, J. K., Carraway, K. L., & Sweeney, C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5962 · Cited by 473 · see citing works

An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation

Schoeberl, B., Faber, A. C., Li, D., Liang, M.-C., Crosby, K., Onsum, M., Burenkova, O., Pace, E., Walton, Z., Nie, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3145 · Cited by 264 · see citing works

Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition

Rexer, B. N., Ham, A.-J. L., Rinehart, C., Hill, S., de Matos Granja-Ingram, N., González-Angulo, A. M., Mills, G. B., Dave, B., Chang, J. C., Liebler, D. C., et al. (2011) · Oncogene · doi:10.1038/onc.2011.130 · Cited by 139 · see citing works

Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors

Chakrabarty, A., Bhola, N. E., Sutton, C., Ghosh, R., Kuba, M. G., Dave, B., Chang, J. C., & Arteaga, C. L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2440 · Cited by 130 · see citing works

Preclinical In Vivo Modeling of Cytokine Release Syndrome Induced by ErbB-Retargeted Human T Cells: Identifying a Window of Therapeutic Opportunity?

van der Stegen, S. J. C., Davies, D. M., Wilkie, S., Foster, J., Sosabowski, J. K., Burnet, J., Whilding, L. M., Petrovic, R. M., Ghaem-Maghami, S., Mather, S., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301523 · Cited by 126 · see citing works

H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3

Chakrabarty, A., Rexer, B. N., Wang, S. E., Cook, R. S., Engelman, J. A., & Arteaga, C. L. (2010) · Oncogene · doi:10.1038/onc.2010.257 · Cited by 102 · see citing works

Resistance to EGFR-Targeted Therapy: A Family Affair

Vlacich, G., & Coffey, R. J. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.006 · Cited by 61 · see citing works

Neuregulin 1-HER axis as a key mediator of hyperglycemic memory effects in breast cancer

Park, J., Sarode, V. R., Euhus, D., Kittler, R., & Scherer, P. E. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214400109 · Cited by 44 · see citing works

Neratinib-Plus-Cetuximab in Quadruple-WT ( <i>KRAS, NRAS, BRAF, PIK3CA</i> ) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study

Jacobs, S. A., Lee, J. J., George, T. J., Wade, J. L., Stella, P. J., Wang, D., Sama, A. R., Piette, F., Pogue-Geile, K. L., Kim, R. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1831 · Cited by 27 · see citing works

Comparison of the therapeutic outcome between gefitinib and erlotinib in female patients with non-small-cell lung cancer

문대성, 장태원, Ok, C. H., 정만홍, 김도현, & 최인수 (2009) · The Korean Journal of Internal Medicine

Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.

Shao, Y., Lin, C., & Yang, C.-H. (2010) · PubMed · Cited by 13 · see citing works

Successful Treatment of Non-small Cell Lung Cancer with Gefitinib after Severe Erlotinib-related Hepatotoxicity

Kunimasa, K., Yoshioka, H., Iwasaku, M., et al. (2012) · Internal Medicine · doi:10.2169/internalmedicine.51.6285 · Cited by 26 · see citing works

Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment

Сонг, Zheng-bo, Yu, et al. (2011) · 中华医学杂志：英文版

Μελέτη της αντινεοπλασματικής δράσης των αναστολέων των τυροσινικών κινασών [ZD1839 (Gefitinib) και GW572016 (Lapatinib)] στα κυκλοφορούντα μικρομεταστατικά κύτταρα του αίματος σε ασθενείς με καρκίνο μαστού

Καλυκάκη, Α. (2015) · doi:10.12681/eadd/36635